<DOC>
	<DOCNO>NCT00102492</DOCNO>
	<brief_summary>This placebo-controlled , fix dose study evaluate efficacy safety GW679769 subject major depressive disorder .</brief_summary>
	<brief_title>Study Of GW679769 In Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Inclusion criterion : Subjects must ability comprehend key component consent form . Subject must meet DSMIVTR ( Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ) criteria current MDE ( major depressive episode ) least 8 week prior Screening Visit . If female , subject must practice acceptable method birth control . Subjects must rating score outline . Exclusion criterion : Subjects whose symptom MDE well account another diagnosis . Subjects history schizophrenia , schizoaffective disorder bipolar disorder . Subjects positive urine test illicit drug use and/or history substance abuse alcohol dependence within past 12 month . Subjects unstable medical disorder . If female , pregnant lactating . Subjects receive ECT ( electroconvulsive therapy ) TMS ( transcranial magnetic stimulation ) within 6 month precede screen ever homicidal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Major Depression</keyword>
	<keyword>Mood Disorders</keyword>
	<keyword>Major Depressive Episode</keyword>
</DOC>